Lite Strategy Q1 EPS $0.48 Up From $(0.12) YoY
Lite Strategy Inc LITS
$0.96
▲ +0.59%
(+$0.01)
📅 Earnings This Week
Open
$0.96
Prev Close
$0.95
Day Range
$0.90 – $1.00
52W Range
$0.69 – $2.26
Market Cap
$28.38M
Beta
0.14
EPS (TTM)
$-1.74
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2003-12-18 |
| Shares Out. | 30,410,000 |
| Website | litestrategy.com ↗ |
| Phone | 13026587581 |
| Employees | 5 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | $16.0M |
| Free Cash Flow | -$6.8M |
| Total Assets | $58.4M |
| Total Liabilities | $1.7M |
| Equity | $56.7M |
About Lite Strategy Inc
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Lite Strategy Inc is a publicly traded company under the ticker symbol LITS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2025-11-01)